论文部分内容阅读
细胞毒类药物经腹腔给药其在腹膜的浓度远高于全身化疗。许多医院用细胞毒类药物腹腔化疗治疗卵巢癌。已证实顺铂是最有希望的腹腔化疗药物,特别适合于腹腔肿瘤结节<1～2cm直径者。已表明二羟二蒽酮和干扰素-α2腹腔给药对卵巢癌有明确抗肿瘤作用。鉴于以上认识以及顺铂与这些药物之间无交叉对抗,作者研究了这些药物联合腹腔化疗的疗效与毒性。 1986～1991年,41例非选择性卵巢癌,全身化疗后探查表明残瘤≤2cm,平均年龄57岁(39～70)。无腹腔外转移。ECOG体力状况计分0～
Cytotoxic drugs by intraperitoneal administration in the peritoneal concentration is much higher than systemic chemotherapy. Many hospitals use cytotoxic drugs to treat ovarian cancer by intraperitoneal chemotherapy. Cisplatin has proven to be the most promising intraperitoneal chemotherapeutic agent and is particularly suitable for those with <1 to 2 cm diameter in nodular tumor tumors. It has been shown that intraperitoneal administration of dihydroxyanthratone and interferon-α2 has a clear anti-tumor effect on ovarian cancer. In view of the above understanding and the lack of cross-reaction between cisplatin and these drugs, the authors studied the efficacy and toxicity of these drugs in combination with intraperitoneal chemotherapy. From 1986 to 1991, 41 cases of non-selective ovarian cancer, after chemotherapy showed that the detection of residual tumor ≤ 2cm, mean age 57 years (39 ~ 70). No extraperitoneal metastases. ECOG physical status score 0 ~